Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 120 resultados

DTRIP4H: Enabling Decentralised Digital Twin Era in existing Research Infrastructures for Predictive Prevent... In the face of a rapidly advancing digital healthcare terrain, the DTRIP4H project emerges as a momentous effort to revolutionize predictive...
2024-10-23 - 2028-12-31 | Financiado

SIMIACCI: Sustainable Intelligent Management of Indoor Air Quality for the Culture and Creative Industries EIT URBAN MOBILITY INNOVATION HUB C participó en un HORIZON EUROPE: HORIZON-CL2-2024-HERITAGE-01 Climate transition is imposed to all sectors of the EU economy, including CCI, especially through more efficient use of resources. Amongst C...
2024-10-01 - 2028-12-31 | Financiado

SOFAR: SOuthern aFrica research cApacity netwoRk The SOuthern aFrica Research cApacity netwoRk (SOFAR) will train a generation of innovative world class and resilient African scientists, cl...
2024-09-13 - 2029-03-31 | Financiado

ERDERA: EUROPEAN RARE DISEASES RESEARCH ALLIANCE EIT URBAN MOBILITY INNOVATION HUB C participó en un HORIZON EUROPE: HORIZON-HLTH-2023-DISEASE-07 The European Rare Diseases Research Alliance (ERDERA) aims to improve the health and well-being of the 30 million people living with a rare...
2024-08-20 - 2031-08-31 | Financiado

T-RAFIC: Training network for tracking and controlling therapeutic immune cells in cancer Cancer immunotherapies have been established in a growing number of clinical indications and the pace of development is massively accelerat...
2024-07-16 - 2029-03-31 | Financiado

SMARTY: Scalable and Quantum Resilient Heterogeneous Edge Computing enabling Trustworthy AI SMARTY invokes a cloud-edge continuum, made from heterogeneous systems, that protects data-in-transit and data-in-process in order to offer...
2024-06-28 - 2027-05-31 | Financiado

CATACLIS: Cancer tailored next generation cellular therapies EIT URBAN MOBILITY INNOVATION HUB C participó en un HORIZON EUROPE: ERC-2023-COG "Cellular therapies are commonly used to treat hematological cancers but have yet to be established in solid oncology. Their evolution has b...
2024-04-30 - 2029-09-30 | Financiado

HoloSurge: Multimodal 3D Holographic tool and real time Guidance System with point of care diagnostics for surg... Perioperative care is an intricate process that encompasses 1) preoperative evaluation, surgical planning and preparation; 2) intraoperative...
2023-12-07 - 2027-12-31 | Financiado

ORTHO-ALLO-UNION: ORTHOpaedic treatment with ALLOgenic combined ATMP in long bone fracture delayed UNION and non union... EIT URBAN MOBILITY INNOVATION HUB C participó en un HORIZON EUROPE: HORIZON-HLTH-2023-TOOL-05 Bone fracture with delay or failure to heal is a condition with huge health impact. Although only a small proportion of long bone fractures...
2023-11-28 - 2028-11-30 | Financiado

Yellow4FLAVI: Deconstructing the protective immunity of yellow fever virus 17D to inform flavivirus vaccine design EIT URBAN MOBILITY INNOVATION HUB C participó en un HORIZON EUROPE: HORIZON-HLTH-2023-DISEASE-03 While endemic to the tropics, flaviviruses like Zika, dengue, West Nile or yellow fever virus are re-emerging pathogens of global health con...
2023-11-14 - 2028-12-31 | Financiado

PREDICTOM: PREDICTION OF ALZHEIMER S DISEASE USING AN AI DRIVEN SCREENING PLATFORM EIT URBAN MOBILITY INNOVATION HUB C participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-03-single-stage Alzheimer’s disease (AD) and related disorders leading to dementia are associated with staggering costs and suffering. Recently, there has b...
2023-10-30 - 2027-10-31 | Financiado

ImmGenDC: Dissecting the context-specificity of genetic immune regulation in plasmacytoid dendritic cells EIT URBAN MOBILITY INNOVATION HUB C participó en un HORIZON EUROPE: ERC-2022-STG Antiviral immunity and autoimmune diseases exhibit high interindividual variability. Despite intensive research, the genetic and molecular b...
2023-08-17 - 2028-09-30 | Financiado

NEPIT: Network for Evaluation of Propagation and Interference Training EIT URBAN MOBILITY INNOVATION HUB C participó en un HORIZON EUROPE: HORIZON-MSCA-2022-DN-01 The widespread use of modern communication systems, the higher penetration of automated systems in automotive engineering, surgery, high-tec...
2023-06-20 - 2028-02-29 | Financiado

MIRACLE: MultiomIcs based Risk stratification of Atherosclerotic CardiovascuLar disEase EIT URBAN MOBILITY INNOVATION HUB C participó en un HORIZON EUROPE: HORIZON-EIC-2022-PATHFINDERCHALLENGES-01 Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Aside from asymptomatic manifestations, the firs...
2023-06-14 - 2027-09-30 | Financiado

FCDI: Future Connectivity and Digital Infrastructure EIT URBAN MOBILITY INNOVATION HUB C participó en un HORIZON EUROPE: HORIZON-SESAR-2022-DES-IR-01 The WA3.1 FCDI project aims to specify and develop the future Technologies coming from the CNS in order to support and manage the Operationa...
2023-06-14 - 2026-05-31 | Financiado

ARAMIZDA: Understanding divisions and fostering dialogue among Berlin’s Turkish speaking communities EIT URBAN MOBILITY INNOVATION HUB C tramitó un HORIZON EUROPE: HORIZON-MSCA-2022-PF-01 After 60 years of migration in countless waves, Germany’s Turkish-speaking communities are complex and diverse. Routinely lumped together by...
2023-05-12 - 2026-02-13 | Financiado

MEKanics: Cell mechanics of megakaryocytes in 3D tissues - deciphering mechanobiology of platelet formation EIT URBAN MOBILITY INNOVATION HUB C participó en un HORIZON EUROPE: ERC-2022-STG Homeostatic platelet counts are crucial for vascular integrity and vital to life. Megakaryocytes (MEKs) are giant hematopoietic cells formin...
2023-05-04 - 2028-12-31 | Financiado

STRATA-FIT: Stratification of Rheumatoid Arthritis: CompuTational models to personalise mAnagement strategies fo... EIT URBAN MOBILITY INNOVATION HUB C participó en un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-12-two-stage Difficult-to-treat rheumatoid arthritis (D2T RA) is an area of huge unmet medical need with major socio-economic consequences for patients a...
2023-04-07 - 2029-04-30 | Financiado

T2Lead: Define a lead candidate for clinical development of a novel T cell therapy EIT URBAN MOBILITY INNOVATION HUB C participó en un HORIZON EUROPE: ERC-2022-POC2 Acute myeloid leukemia (AML) is a disease with a poor prognosis, especially for such patients either failing initial treatment or relapsing...
2023-03-13 - 2025-02-28 | Financiado

EIT Urban Mobility Innovation Hub Centra...